Resolvyx to Present Data on Novel Resolvin Drug Candidates for Eye Disease at ARVO Annual Meeting

BEDFORD, Mass.--(BUSINESS WIRE)--Apr 24, 2008 - Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that new preclinical data on its resolvin drug candidates will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held April 27 to May 1, 2008.

"With a total of eight oral and poster presentations, we are delighted to have such a strong presence at ARVO, which is the premier global ocular meeting," said Per Gjorstrup, Ph.D., M.D., Co-Founder and Chief Medical Officer of Resolvyx. "Due to their unique mechanism of action in resolving inflammation and protecting healthy eye tissue, we have studied resolvins in multiple ocular indications, including retinal and dry eye diseases."

The schedule and meeting place for the sessions, together with the abstract information, are listed below: -0-

Oral/Paper Presentations:


Date & Time: Tuesday, Apr 29 2008 9:30 AM - 9:45 AM

Session Title: RPE Cell Biology

Session Number: 309

Abstract: #2438

Title: Oxidative Stress-Induced Apoptosis and Pro-Inflammatory Cox-2

 Expression Are Down-Regulated by Resolvins in Retinal Pigment-

 Epithelial (arpe-19) Cells

Organizing Section: Retinal Cell Biology

Location: Floridian Ballroom A


Date & Time: Thursday, May 1 2008 11:30 AM - 11:45 AM

Session Title: Regulation of CNV in Animal Models

Session Number: 529

Abstract: #5414

Title: Resolvin E1 or a Resolvin E1 Analog Inhibits Vascular Leakage

 in Experimental Choroidal Neovascularization (CNV)

Organizing Section: Retinal Cell Biology

Location: Floridian Ballroom A


Date & Time: Thursday, May 1 2008 11:00 AM - 11:15 AM

Session Title: Regulation of CNV in Animal Models

Session Number: 529

Abstract: #5412

Title: Systemic Neuroprotectin D1 (NPD1) Is a Potent Inhibitor of

 Laser-Induced Choroidal Neovascularization

Organizing Section: Retinal Cell Biology

Location: Floridian Ballroom A


Poster Presentations:


Date & Time: Sunday, Apr 27 2008 8:30 AM - 10:15 AM.

Session Title: Treating Dry Eye Disease

Session Number: 106

Abstract: #121/A148

Title: The Resolvin E1 Analogs, RX-10065 and RX-10005 Improve Tear

 Production and Decrease Inflammation in a Mouse Dry Eye Model

Organizing Section: Cornea

Location: Exhibit Hall B/C


Date & Time: Sunday, Apr 27 2008 8:30 AM - 10:15 AM.

Session Title: Treating Dry Eye Disease

Session Number: 106

Abstract: #122/A149

Title: Resolvins Protect Against Goblet Cell Loss and Reduce Corneal

 Epithelial Barrier Disruption in a Murine Model of KCS

Organizing Section: Cornea

Location: Exhibit Hall B/C


Date & Time: Sunday, Apr 27 2008 8:30 AM - 10:15 AM

Session Title: Treating Dry Eye Disease

Session Number: 106

Abstract: #125/A152

Title: Resolvins Inhibit Hypertonicity-Induced Proinflammatory

 Cytokine Release by Suppressing Mapk Pathway Activation in Human

 Corneal Epithelial Cells

Organizing Section: Cornea

Location: Exhibit Hall B/C


Date & Time: Tuesday, Apr 29 2008 11:15 AM - 1:00 PM

Session Title: Drug Delivery II

Session Number: 358

Abstract: #3179/D912

Title: Resolvin Analogs With Pharmacokinetic Properties Suitable for

 Topical Administration to Treat Ocular Diseases

Organizing Section: Physiology/Pharmacology

Location: Exhibit Hall B/C


Date & Time: Tuesday, Apr 29 2008 3:00 PM - 4:45 PM

Session Title: Corneal Epithelium: Culture/Wound Healing/Development

Session Number: 384

Abstract: #3396/A250

Title: Resolvins Stimulate Human Corneal Epithelial Cell Migration

Organizing Section: Cornea/Anatomy Pathology

Location: Exhibit Hall B/C

About Resolvins

Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. In particular, resolvins act to protect healthy tissue during an immuno-inflammatory response to infection, injury or other environmental challenge, and then act to resolve inflammation and promote healing after the environmental insult has passed. Resolvins have shown highly potent efficacy in pre-clinical models of asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others.

Resolvins are potential drug candidates to treat a broad range of acute and chronic diseases caused by a failure to resolve the inflammatory response and restore immune homeostasis. Such diseases include auto-immune diseases (like Crohn's disease, psoriasis and rheumatoid arthritis), allergic diseases (like asthma) and chronic inflammatory disease (like atherosclerosis, degenerative retinal diseases, chronic dry eye and Alzheimer's disease). Resolvins offer an entirely novel biological approach to treating significant inflammatory diseases, with a decreased potential for immuno-suppression.

About Resolvyx Pharmaceuticals

Resolvyx Pharmaceuticals is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases and their complications. Resolvyx's drug R&D programs are focused on characterizing and developing resolvin-based compounds. With its experienced management team, world-class scientists and leading investors, Resolvyx is well-positioned to capitalize on its extensive portfolio of more than 55 patents and applications. The company's headquarters are in Bedford, Massachusetts.

For additional information, please visit www.resolvyx.com.

Contact

Yates Public Relations
Kathryn Morris, 845-635-9828

Posted: April 2008

View comments

Hide
(web1)